Sysmex Co. (OTCMKTS:SSMXY) Short Interest Update

Sysmex Co. (OTCMKTS:SSMXY) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 369,500 shares, a growth of 627.4% from the August 31st total of 50,800 shares. Based on an average daily volume of 765,400 shares, the short-interest ratio is presently 0.5 days.

Sysmex Stock Performance

Shares of OTCMKTS SSMXY traded up $0.26 during trading hours on Friday, reaching $19.42. The stock had a trading volume of 30,231 shares, compared to its average volume of 264,083. The firm has a 50-day moving average of $18.22 and a 200-day moving average of $17.21. The firm has a market cap of $12.22 billion, a price-to-earnings ratio of 38.55 and a beta of 0.84. The company has a current ratio of 3.23, a quick ratio of 2.40 and a debt-to-equity ratio of 0.11. Sysmex has a fifty-two week low of $14.38 and a fifty-two week high of $29.78.

Sysmex (OTCMKTS:SSMXY) last announced its earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share (EPS) for the quarter. The business had revenue of $718.13 million for the quarter. Sysmex had a net margin of 10.25% and a return on equity of 11.15%. Equities research analysts predict that Sysmex will post 0.65 earnings per share for the current year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.